MATERIALS & CONSUMABLE GOODSNo sanctions match · screened 20 Nov 2026

AstraZeneca

astrazeneca.comUpdated 8 Nov 2026

Strategic intent

AstraZeneca is a global biopharmaceutical company that discovers, develops, and commercializes prescription medicines, primarily focusing on oncology, rare diseases, cardiovascular, renal, metabolism, respiratory, and immunology therapies.

Key market signals

  • 2026-11: AstraZeneca submitted a non-binding $10 billion proposal to acquire obesity and rare-disease drugmaker Rhythm Pharmaceuticals.
  • 2026-10: AstraZeneca launched its 'Reshaping for Sustainable Growth' program, a three-year restructuring plan to achieve $1.5 billion in annualized savings by 2029.
  • 2026-10: AstraZeneca agreed to invest $2 billion in Summit Therapeutics to collaborate on combining oncology assets sonesitatug vedotin and ivonescimab.
  • 2026-10: Enhertu received EU approval as an adjuvant treatment for patients with residual HER2-positive early breast cancer.
  • 2026-11: AstraZeneca scheduled the start of a Phase 3 clinical trial evaluating durvalumab with FLOT chemotherapy in Chinese gastric cancer patients.

Financial health

  • For the nine months ended September 30, 2026, AstraZeneca reported total revenue of $46.881 billion, representing an 8% increase at actual exchange rates and 7% at constant exchange rates (CER) compared to the prior year period (https://www.stocktitan.net/news/AZN/astra-zeneca-results-9-m-and-q3-2026-b827b120261029-797v97v97v.html).
  • Core Earnings Per Share (EPS) for the first nine months of 2026 rose 14% to $8.00 (https://www.stocktitan.net/news/AZN/astra-zeneca-results-9-m-and-q3-2026-b827b120261029-797v97v97v.html).
  • Operating cash flow was $10.9 billion for the first nine months of 2026, down from $12.2 billion in the prior year period, primarily due to working-capital effects from Farxiga's U.S. loss of exclusivity (https://www.alpha-sense.com/blog/earnings/astrazeneca-plc-earnings-q3-2026-analysis-highlights/).

Impact & compliance

Social ImpactModern Slavery Statement (2025)Scope 3 data: comprehensiveThird-party assured

Forensic audit

  • Jul 2026: On July 9, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a Delaware district court's judgment as …
  • May 2026: In May 2026, AstraZeneca entered into a global settlement agreement with the University of Sheffield, resolving …
More findings — log in

Proprietary analysis

  • Strategic fit

    AI-calculated strategic alignment score

    Log in to see
  • Cultural fit

    Trust and integrity score

    Log in to see
  • Alignment dimensions

    How this supplier scores against each of your strategic imperatives

    Log in to see
  • Full forensic analysis

    Complete ESG audit, modern slavery risk assessment, labour sentiment analysis, and observed contradictions with evidence trails.

    Log in to see

Want the full analysis?

Strategic and cultural fit scoring, full forensic detail and alignment dimensions, for this supplier and your own.